{"ModuleTitle": "Company Description", "CompanyName": "DexCom, Inc.", "Symbol": "DXCM", "Address": "6340 SEQUENCE DRIVE, SAN DIEGO, California, 92121, United States of America", "Phone": "8582000200", "Industry": "Medical/Dental Instruments", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a medical device company primarily focused on the design, development and\r\ncommercialization of continuous glucose monitoring, or CGM, systems for use by\r\npeople with diabetes and by healthcare providers. We received approval from the\r\nUnited States (U.S.) Food and Drug Administration, or FDA, and commercialized\r\nour first product in 2006. We launched our latest generation system, the DexCom\r\nG6\u00ae integrated Continuous Glucose Monitoring System, or G6, in 2018. Unless the\r\ncontext requires otherwise, the terms \"we,\" \"us,\" \"our,\" the \"company,\" or\r\n\"DexCom\" refer to DexCom, Inc. and its subsidiaries.\r\nProducts\r\nDexCom G6\u00ae \r\nIn March 2018, we obtained marketing authorization from the FDA for the G6 via\r\nthe de novo process.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f13%2f0001093557-20-000029.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Andrew K. Balo", "title": "EVP-Clinical Affairs, Regulatory Strategies"}, {"name": "Jacob Leach", "title": "Chief Technology Officer"}, {"name": "Kevin Ronald Sayer", "title": "Chairman, President & Chief Executive Officer"}, {"name": "Quentin S. Blackford", "title": "Chief Operating & Financial Officer"}, {"name": "Shelly R. Selvaraj", "title": "Senior Vice President-Information Technology"}], "Number_of_employees": ["3,900"], "Subsidiaries": ["NO INFO"]}